The aim of this study is to evaluate the frequency of probable sarcopenia and sarcopenia in patients with primary Sjögren syndrome and to investigate the effects of sarcopenia on functional status, muscle strength, and quality of life. Adult patients diagnosed with primary Sjögren syndrome will be included in the study. Muscle strength, muscle mass, physical performance, and functional status will be assessed using various evaluation methods
Primary Sjögren syndrome is a chronic autoimmune inflammatory disease that may affect the musculoskeletal system. Sarcopenia is characterized by decreased muscle mass and muscle strength and may lead to impaired physical performance and functional capacity. In this cross-sectional study, the presence of probable sarcopenia and sarcopenia in adult patients with primary Sjögren syndrome will be evaluated. Demographic characteristics, disease duration, and clinical findings of the participants will be recorded. Muscle strength will be assessed using handgrip strength testing, and physical performance will be evaluated using functional performance tests. In addition functional status scales will be administered. The study aims to determine the effects of sarcopenia on functional status and quality of life in patients with primary Sjögren syndrome.
Study Type
OBSERVATIONAL
Enrollment
120
Although these parameters are frequently assessed in other rheumatological diseases, few studies have previously examined such a wide range of parameters in patients with primary Sjögren's syndrome.
Antalya Training and Research Hospital
Antalya, Turkey (Türkiye)
muscle strength
Muscle strength will be assessed using hand-held dynamometry. Measurements will be recorded in kilograms-force (kgf) and compared between primary Sjögren syndrome patients and healthy controls.
Time frame: 12 month
muscle mass
Muscle mass will be assessed using DEXA. Results will be compared between groups.
Time frame: 12 months
functional status
Functional status will be evaluated using validated functional assessment scales. Scores will be compared between primary Sjögren syndrome patients and healthy controls.
Time frame: 12 months
myostatin
Serum myostatin levels will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between groups.
Time frame: 12 months
follistatin
Serum follistatin levels will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between groups.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.